Recent Updates
Recently added Catalysts
ALGS Positive Sentiment Score: 75/100

Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference

Key Takeaway: Aligos Therapeutics, a clinical stage biopharmaceutical company, has announced its participation in the 2023 Piper Sandler Healthcare Conference. Lawrence M. Blatt, Ph.D., MBA, the CEO, will present on November 30, 2023, at 12:30 p.m. ET. The management team will also engage in one-on-one meetings with investors during the event. Aligos aims to lead in developing therapies for liver and viral diseases, targeting conditions with significant unmet medical needs.

Market Sentiment Analysis

POSITIVE FACTORS

  • Aligos Therapeutics is participating in a reputable healthcare conference.
  • The presentation may highlight advancements in novel therapeutics for liver and viral diseases.
  • The company has a strong focus on unmet medical needs, indicating potential market impact.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, and the Aligos management team, will present at the 2023 Piper Sandler Healthcare Conference being held in New York on Thursday, November 30, 2023 at 12:30 p.m. ET.
Piper Sandler Healthcare Conference Information:
Date Thursday, November 30, 2023
Time: 12:30 p.m. ET
Presenter: Lawrence Blatt, Ph.D., MBA, CEO of Aligos
Webcast: Link here
A replay of the session will be available following the conference for 90-days through the Aligos investor section of the website https://investor.aligos.com/.
The Aligos management team will also participate in investor 1x1 meetings during the conference. Please contact your Piper Sandler representative to schedule one-on-one meetings with Aligos during the conference.
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver and viral diseases. Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver and viral diseases to discover and develop potentially best in class therapeutics for nonalcoholic steatohepatitis (NASH) and viruses with high unmet medical need such as coronaviruses and chronic hepatitis B (CHB).
LifeSci Communications

Frequently Asked Questions

When will Aligos present at the Piper Sandler Conference?

Aligos will present on November 30, 2023, at 12:30 p.m. ET.

Who will present for Aligos at the conference?

Lawrence M. Blatt, Ph.D., MBA, CEO of Aligos, will present.

How can I access the conference replay?

A replay will be available for 90 days on Aligos' investor website.

What diseases does Aligos focus on treating?

Aligos specializes in liver and viral diseases, including NASH and CHB.

When was Aligos Therapeutics founded?

Aligos Therapeutics was founded in 2018.

Last updated: Nov 20, 2023